Stockscreener 앱 받기
14.78
4.08%
0.58
시간 외 거래:
14.78
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Trend Tracker for (DNLI) - Stock Traders Daily
Denali Therapeutics stock hits 52-week low at $13.95 By Investing.com - Investing.com South Africa
Denali Therapeutics stock hits 52-week low at $13.95 - Investing.com India
Exponential Growth Expected for Blood Brain Barrier Market With - openPR
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha
Why You Shouldn't Bet Against Denali (DNLI) Stock - Barchart
(DNLI) On The My Stocks Page - Stock Traders Daily
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World
Why Denali Therapeutics Shares Are Tumbling - TipRanks
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World
How the (DNLI) price action is used to our Advantage - Stock Traders Daily
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Denali's ALS programme suffers another setback - pharmaphorum
What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World
B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks
Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks
DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - Marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World
DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey
Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating - Marketscreener.com
Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating - Marketscreener.com
Denali Therapeutics: Why Analysts Remain Optimistic - TipRanks
Denali Therapeutics’ (DNLI) “Outperform” Rating Reiterated at William Blair - Defense World
What is HC Wainwright’s Forecast for DNLI Q1 Earnings? - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00 - Defense World
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus - MSN
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In - Insider Monkey
Y Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
William Blair Reiterates "Outperform" Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing - MSN
Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Wedbush Adjusts Price Target on Denali Therapeutics to $32 From $33, Maintains Outperform Rating - Marketscreener.com
Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating - TipRanks
Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating - TipRanks
Denali stock price target cut to $80 by H.C. Wainwright - Investing.com
Denali Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Denali Therapeutics reports Q4 EPS (67c), consensus (85c) - TipRanks
Denali Therapeutics Files For Mixed Shelf Size Not DisclosedSEC Filing -February 27, 2025 at 05:14 pm EST - Marketscreener.com
Denali Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Denali Therapeutics Signs New Equity Distribution Deal - TipRanks
Denali Therapeutics Inc. SEC 10-K Report - TradingView
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Can Denali's Hunter Syndrome Drug Breakthrough Offset $422M Annual Loss? - StockTitan
0.39%
0.34%
자본화:
|
볼륨(24시간):